natgillin/translations-raw huggingface dataset:
or R3 and R4 may be taken together with the nitrogen atom to which they are attached to form an optionally substituted (C4-C8) heteroaryl or (C4-C8) heterocyclic ring; 
ili R3 i R4 mogu biti uzeti zajedno sa atomom dušika za koji su vezani da se formira po izboru supstituiran (C4-C8) heteroaril ili (C4-C8) heterociklični prsten;
A compound according to claim 1 selected from the following: 
Spoj u skladu sa patentnim zahtjevom 1 koji je odabrano od sljedećeg:
A compound, selected from the following: 
Spoj, odabran od sljedećeg:
The compound for the use according to claim 11, wherein the disease or condition is cancer. 
Spoj za primjenu u skladu sa patentnim zahtjevom 11, pri čemu je bolest ili stanje rak.
The compound for the use of claim 13, wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, multiple myeloma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), pancreatic cancer, liver cancer, hepatocellular cancer, neuroblastoma, other solid tumors or other hematological cancers. 
Spoj za primjenu iz patentnog zahtjeva 13, pri čemu je rak sitnostanični rak pluća, ne-sitnostanični rak pluća, kolorektalni rak, multipli mijelom, akutna mijeloidna leukemija (AML), akutna limfoblastna leukemija (ALL), rak gušterače, rak jetre, hepatostanični rak, neuroblastom, ostali čvrsti tumori ili ostali hematološki karcinomi.
The compound for the use of claim 13, wherein the cancer is small cell lung cancer, non-small cell lung cancer, colorectal cancer, multiple myeloma or AML. 
Spoj za primjenu iz patentnog zahtjeva 13, pri čemu je rak sitnostanični rak pluća, ne-sitnostanični rak pluća, kolorektalni rak, multipli mijelom ili AML.
passing a composition comprising an antibody of interest and various contaminants through an ion exchange membrane, wherein the antibody and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pI of the antibody to enhance the charge of the antibody and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the antibody and at least one contaminant; 
prolaska formulacije koja obuhvaća željeno protutijelo i različite kontaminante kroz membranu za ionsku izmjenu, pri čemu protutijelo i membrana imaju suprotan naboj, pri radnim uvjetima koji obuhvaćaju pufer koji ima pH dostatno različit od pI protutijela kako bi se poboljšao naboj protutijela te nisku učinkovitu ionsku snagu kako bi se spriječila zaštita naboja puferskim ionima, što uzrokuje da se membrana veže za protutijelo te za najmanje jedan kontaminant;
overloading the ion exchange membrane to a load density of 1000 - 5000 g/L such that at least one contaminant remains bound to the membrane while the antibody of interest is primarily in the effluent; 
preopterećenja membrane za ionsku izmjenu na udarnu gustoću od 1000 do 5000 g/L tako da najmanje jedan kontaminant ostaje vezan na membranu dok je protutijelo od interesa prvenstveno u efluentu;
subjecting the membrane effluent comprising the antibody of interest to a ion exchange chromatography step of similar charge as the previous membrane, and 
podvrgavanja efluenta membrane koji sadrži željeno protutijelo koraku kromatografije ionske izmjene sličnog naboja kao i prethodna membrana, i
recovering the purified antibody from the effluent of the charged ion exchange chromatography step. 
oporavka pročišćenog protutijela iz efluenta prema koraku kromatografije izmjene nabijenog iona.
The method of claim 1 wherein the ion exchange membrane has a pore size of 0.1 to 100 µm. 
Postupak prema patentnom zahtjevu 1, naznačen time, da membrana ionske izmjene ima veličinu pore od 0,1 do 100 µm.
passing a composition comprising an antibody of interest and various contaminants through a cation exchange membrane, wherein the antibody and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH of about 1 to about 5 pH units below the pI of the antibody and a conductivity of ≤ about 40 mS/cm, which cause the membrane to bind the antibody and at least one contaminant, 
prolaska formulacije koja obuhvaća željeno protutijelo i različite kontaminante kroz membranu za kationsku izmjenu, pri čemu protutijelo i membrana imaju suprotan naboj, pri radnim uvjetima koji obuhvaćaju pufer koji ima pH od otprilike 1 do otprilike 5 pH jedinica ispod pI protutijela i provodljivost od ≤ otprilike 40 mS/cm, što uzrokuje vezivanje membrane za protutijelo te za barem jedan kontaminant,
overloading the cation exchange membrane to a load density of 1000 - 5000 g/L such that at least one contaminant remains bound to the membrane while the antibody of interest is primarily in the effluent; 
preopterećenja membrane za kationsku izmjenu na udarnu gustoću od 1000 do 5000 g/L tako da najmanje jedan kontaminant ostaje vezan na membranu dok je željeno protutijelo prvenstveno u efluentu;
subjecting the membrane effluent comprising the antibody of interest to a cation exchange chromatography purification step, and 
podvrgavanja efluenta membrane koji sadrži željeno protutijelo koraku pročišćavanja kromatografijom kationske izmjene, i
recovering the purified antibody from the effluent of the cation exchange chromatography purification step. 
oporavka pročišćenog protutijela iz efluenta prema koraku pročišćavanja kromatografijom kationske izmjene.
The method of claim 4 wherein the pH is about 1 to about 2 pH units below the pI of the antibody. 
Postupak prema patentnom zahtjevu 4, naznačen time, da je pH otprilike 1 do otprilike 2 pH jedinice ispod pI protutijela.
The method of claim 4 wherein the pH is about 1 pH unit below the pI of the antibody. 
Postupak prema patentnom zahtjevu 4, naznačen time, da je pH otprilike 1 pH jedinica ispod pI protutijela.
overloading the anion exchange membrane to a load density of 1000 - 5000 g/L such that at least one contaminant remains bound to the membrane while the antibody of interest is primarily in the effluent; 
preopterećenja membrane za anionsku izmjenu na udarnu gustoću od 1000 do 5000 g/L tako da najmanje jedan kontaminant ostaje vezan na membranu dok je željeno protutijelo prvenstveno u efluentu;
subjecting the membrane effluent comprising the antibody of interest to a anion exchange chromatography purification step, and 
podvrgavanja efluenta membrane koji sadrži željeno protutijelo koraku pročišćavanja kromatografijom anionske izmjene, te
recovering the purified antibody from the effluent of the anion exchange chromatography purification step. 
oporavka pročišćenog protutijela iz efluenta prema koraku pročišćavanja kromatografijom anionske izmjene.
The method of any of claims 1 to 19 wherein the membrane is a mixed mode adsorber. 
Postupak prema patentnim zahtjevima od 1 do 19, naznačen time, da je membrana adsorbent mješovitog načina rada.
The method of claims 1 to 27 wherein the antibody is a monoclonal antibody. 
Postupak prema patentnim zahtjevima od 1 do 27, naznačen time, da je protutijelo monoklonsko protutijelo.
"heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, 
"heteroaril" označava bilo koju mono- ili bi-cikličku skupinu sastavljenu od 5 do 10 članova prstena, koja ima najmanje jednu aromatsku polovicu i sadrži od 1 do 3 heteroatoma odabrana od kisika, sumpora i dušika,
"cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, 
"cikloalkil" označava bilo koju mono- ili bi-cikličku ne-aromatsku karbocikličku skupinu koja sadrži od 3 do 10 članova prstena,
Compounds according to claim 1, wherein at least one the groups selected from R2, R3, R4 and R5 does not represent a hydrogen atom. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da najmanje jedna od skupina koje su odabrane od R2, R3, R4 i R5 ne predstavlja vodikov atom.
Compounds according to claim 1, wherein X represents a C-R4 group. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da X predstavlja C-R4 skupinu.
Compounds according to claim 1, wherein Y represents a C-R3 group. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da Y predstavlja C-R3 skupinu.
Compounds according to claim 1, wherein R4 and R5 represent a hydrogen atom. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R4 i R5 predstavljaju atom vodika.
Compounds according to claim 1, wherein R7 represents a hydrogen atom, an optionally substituted linear or branched (C1-C6)alkyl group, a -CHRaRb group, or a heteroarylalkyl(C1-C6) group. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R7 predstavlja atom vodika, po izboru supstituiranu ravnu ili razgrananu (C1-C6)alkilnu skupinu, -CHRaRb skupinu ili heteroarilalkil(C1-C6) skupinu.
Pharmaceutical composition for use according to claim 30 for the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 30, naznačen time, što je namijenjen liječenju karcinoma mokraćnog mjehura, mozga, dojke i maternice, kroničnih limfoidnih leukemija, karcinoma debelog crijeva, jednjaka i jetre, limfoblastičnih leukemija, akutnih mijeloidnih leukemija, limfoma, melanoma, malignih hemopatija, mijeloma, karcinoma jajnika, karcinoma pluća ne-malih stanica, karcinoma prostate, karcinoma gušterače i karcinoma pluća malih stanica.
Use of a pharmaceutical composition according to claim 28 in the manufacture of medicaments for use in the treatment of cancers and of auto-immune and immune system diseases. 
Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 28, naznačena time, da se koristi u proizvodnji lijekova za liječenje karcinoma i bolesti autoimunog i imunološkog sustava.
Use of a pharmaceutical composition according to claim 28 in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 28, naznačena time, da se koristi u proizvodnji lijekova za liječenje karcinoma mokraćnog mjehura, mozga, dojke i maternice, kronične limfoidne leukemije, karcinoma debelog crijeva, jednjaka i jetre, limfoblastičnih leukemija, akutnih mijeloidnih leukemija, limfoma, melanoma, malignih hemopatija, karcinoma jajnika, karcinoma pluća ne-malih stanica, karcinoma prostate, karcinoma gušterače i karcinoma pluća malih stanica.
Compound of formula (I) according to any one of claims 1 to 25, or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 25 ili njegova adicijska sol s farmaceutski prihvatljivom kiselinom ili lužinom, naznačen time, što je namijenjen uporabi u liječenju karcinoma mokraćnog mjehura, mozga, dojke i maternice, kronične limfoidne leukemije, karcinoma debelog crijeva, jednjaka i jetre, limfoblastične leukemije, akutne mijeloidne leukemije, limfome, melanoma, maligne hemopatije, mijelome, karcinoma jajnika, karcinoma pluća ne-malih stanica, karcinoma prostate, karcinoma gušterače i karcinoma pluća malih stanica.
Use of a compound of formula (I) according to any one of claims 1 to 25, or an addition salt thereof with a pharmaceutically acceptable acid or base, in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Uporaba spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 25 ili njegove adicijske soli s farmaceutski prihvatljivom kiselinom ili lužinom, naznačena time, da se koristi za proizvodnju lijekova za liječenje karcinoma mokraćnog mjehura, mozga, dojke i maternice, kronične limfoidne leukemije, karcinoma debelog crijeva, jednjaka i jetre, limfoblastične leukemije, akutne mijeloidne leukemije, limfome, melanome, maligne hemopatije, mijelome, karcinoma jajnika, karcinoma pluća ne-malih stanica, karcinoma prostate, karcinoma gušterače i karcinoma malih stanica pluća.
The compound according to claim 1, wherein the compound is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira iz skupine koju čine:
The compound of claim 1, selected from the following group: Lipid Structure 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz sljedeće skupine:
TU104-DLin A compound selected from the following group: 
Spoj, naznačen time što ga se bira iz sljedeće skupine:
A stellate-cell-specific drug carrier comprising the composition of claim 6, and a stellate cell specific amount of a targeting molecule consisting of the structure (retinoid)n-linker-(retinoid)n, wherein n=0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule. The drug carrier of claim 14, further comprising a siRNA molecule. 
Nosač lijekova specifičan za zvjezdaste stanice, naznačen time što sadrži pripravak u skladu s patentnim zahtjevom 6, te količinu ciljajuće molekule specifičnu za zvjezdaste stanice sa strukturom (retinoid)n-spojnica-(retinoid)n, gdje n = 0, 1, 2 ili 3, te gdje spojnica sadrži polietilen-glikol (PEG) ili molekulu sličnu PEG-u.
The pharmaceutical formulation of claim 15, wherein the siRNA is encapsulated by the liposome. 
Farmaceutska formulacija u skladu s patentnim zahtjevom 15, naznačena time što je siRNA inkapsulirana u liposom.
The method according to claim 1, wherein the tiacumicin compound is selected from the group consisting of tiacumicin A, tiacumicin B, tiacumicin C, tiacumicin D, tiacumicin E, tiacumicin F and lipiarmycin. 
Spoj tiakumicina za uporabu prema zahtjevu 1, naznačen time što je spoj tiakumicina odabran iz skupine koja sadrži tiakumicin A, tiakumicin B i njihove analoge, (dialkiltiakumicine i bromotiakumicine), tiakumicin C, tiakumicin D, tiakumicin E, tiakumicin F i lipiarmicin.
is selected from the group consisting of C1-C3alkoxy and —NH2; 
je odabran iz skupine koja sadrži C1-C3alkoksi i-NH2;
The compound according to claim 1 having a Formula (II) wherein R4 is selected from the group consisting of hydrogen, halogen, C1-C3alkyl, cyclopropyl, CHF2, CH2F and CF3. 
Spoj prema zahtjevu 1 ili 2 u skladu s Formulom (II) naznačen time što je R4 odabran iz skupine koja sadrži vodik, halogen, C1-C3alkil, ciklopropil, CHF2, CH2F i CF3.
An overlay for guiding a dental cutting tool in the removal of predetermined tooth structure from a tooth to be treated, the overlay comprising: 
simuliranja pokreta kojeg treba slijediti navedeni alat za rezanje zuba radi uklanjanja zadanog dijela zubne strukture iz navedenog zuba;
a first overlay having a shape and dimensions for guiding at least one dental cutting tool to cut away at least a portion of an upper part of a tooth based on a desired height of remaining tooth structure after removal of the upper part of the tooth to be treated; 
prva presvlaka takvog oblika i dimenzija da služi za vođenje najmanje jednog alata za rezanje zuba radi izrezivanja u najmanju ruku dijela gornjeg dijela zuba na osnovi željene visine preostale zubne strukture nakon uklanjanja gornjeg dijela zuba;
A system for use by a dentist in the removal of predetermined tooth structure from a tooth to be treated, the system comprising: 
Sustav kojeg treba upotrijebiti zubar kod uklanjanja zadane zubne strukture sa zuba kojeg treba liječiti, naznačen time što se sustav sastoji od:
The optical filter of any preceding claim, wherein the optical filter is a bandpass filter, and wherein the passband has a center wavelength in the wavelength range of 800 nm to 1100nm. 
Optički filter prema zahtjevu 1, gdje je optički filter visoko propusni-filter za propuštanje dugih valnih dužina i gdje propusni opseg posjeduje graničnu valnu dužinu u opsegu valnih dužina od 800 nm do 1.100 nm.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claims 1-8 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time, da sadrži terapeutski učinkovitu količinu spoja prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač.
A compound of Claims 1-8 or pharmaceutically acceptable salt thereof, for use in a method of treating a subject for a condition selected from the group consisting of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, pain, atherosclerosis, diabetes, fibrotic diseases, metabolic disorders, cancer, neoplasia, leukemia and lymphoma. 
Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u postupku liječenja subjekta od stanja odabranog iz skupine koja sadrži autoimune poremećaje, kronične upalne poremećaje, akutne upalne poremećaje, auto-upalne poremećaje, bol, aterosklerozu, dijabetes, fibrotične bolesti, metaboličke poremećaje, rak, novotvorine, leukemiju i limfom.
crossing a recombinant yeast strain with a wild yeast strain devoid of deficiencies, wherein the recombinant yeast strain includes at least one copy of an exogenous xylose isomerase gene and at least one additional copy of a D-xylulokinase gene incorporated into the genome and linked to one of the mating traits of the strain, 
križanje rekombinantnog soja kvasca koji je prikladan za metabolizaciju pentoza i otporan na inhibitore fermentacije, s divljim sojem kvasca bez nedostataka, pogodnim za rast na minimalnom mediju, pri čemu rekombinantni soj kvasca sadrži barem jednu kopiju egzogenog gena ksiloza izomeraze i barem jednu dodatnu kopiju gena D-ksilulokinaze uključenu u genom i povezanu s jednim od srodnih svojstava soja i koji se zajednički odvajaju,
performing at least two cycles of genome shuffling by random sporulation and/or hybridization, 
najmanje dva ciklusa miješanja genoma slučajnom sporulacijom i/ili hibridizacijom, bez selekcije između miješanja,
selecting a population obtained in step b) according to a criterion of ability of strains to metabolize xylose, and 
selekciju populacije dobivene u koraku b) prema kriteriju sposobnosti sojeva da metaboliziraju ksilozu,
The process according to claim 11, further comprising a step of genetic transformation by the addition of at least one copy of the GAL2 gene. 
Postupak prema zahtjevu 1, naznačen time što nadalje sadrži korak genetske transformacije dodatkom barem jedne kopije gena GAL2.
A stellate-cell-specific drug carrier comprising the composition of claim 7, embodiment (ii), and a stellate cell specific amount of a targeting molecule consisting of the structure (retinoid)n-linker-(retinoid)n, wherein n=0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule. 
Nosač lijekova specifičan za zvjezdaste stanice, naznačen time što sadrži pripravak u skladu s patentnim zahtjevom 6, te količinu ciljajuće molekule specifičnu za zvjezdaste stanice sa strukturom (retinoid)n-spojnica-(retinoid)n, gdje n = 0, 1, 2 ili 3, te gdje spojnica sadrži polietilen-glikol (PEG) ili molekulu sličnu PEG-u.
is F; or in the case of sub-formula (IIIa-C) 
je F, u slučaju pod-formule (IIIa-C)
is OH; or in the case of sub-formula (IIIa-G) 
je OH, u slučaju pod-formule (IIIa-G)
A kit comprising separate packs of (a) an effective amount of at least one compound according to claim 1 or physiologically acceptable salts, tautomers or stereoisomers thereof, including mixtures thereof in all ratios, and (b) an effective amount of at least one anticancer agent. 
Komplet, naznačen time da se sastoji od odvojenih pakiranja (a) učinkovite količine barem jednog spoja prema jednom od zahtjeva 1 do 13 i/ili njegove fiziološki prihvatljive soli, tautomera i/ili stereoizomera, uključujući njihove smjese u svim omjerima, i (b) učinkovite količine barem jednog antikancerogenog sredstva.
“heteroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, 
"heteroaril" označava bilo koju mono- ili bi-cikličku skupinu sastavljenu od 5 do 10 članova prstena, koja ima najmanje jednu aromatsku polovicu i sadrži od 1 do 3 heteroatoma odabrana od kisika, sumpora i dušika,
“cycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, 
"cikloalkil" označava bilo koju mono- ili bi-cikličku ne-aromatsku karbocikličku skupinu koja sadrži od 3 do 10 članova prstena,
in which each R′ is independent; 
u kojoj je svaki R' neovisan;
The compound according to claim 1, wherein at least one the groups selected from R2, R3, R4 and R5 does not represent a hydrogen atom. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da najmanje jedna od skupina koje su odabrane od R2, R3, R4 i R5 ne predstavlja vodikov atom.
The compound according to claim 1, wherein R4 and R5 represent a hydrogen atom. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R4 i R5 predstavljaju atom vodika.
The compound according to claim 1, wherein R7 represents a hydrogen atom, an optionally substituted linear or branched (C1-C6)alkyl group, a —CHRaRb group, or a heteroarylalkyl(C1-C6) group. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R7 predstavlja atom vodika, po izboru supstituiranu ravnu ili razgrananu (C1-C6)alkilnu skupinu, -CHRaRb skupinu ili heteroarilalkil(C1-C6) skupinu.
The compound according to claim 1, wherein R10 represents -Cy3 or -Cy3-alkyl(C0-C6)-Cy4. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R10 predstavlja -Cy3 ili -Cy3-alkil(C0-C6)-Cy4.
A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant has a dissolved CO2 concentration of 1 to 10%. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što supernatant kulture stanica ima koncentraciju otopljenog CO2 od 1 do 10%, gdje je kultura stanica kontinuirana kultura koju se održava uz gustoću od 1,4 × 106 do 2,8 × 106 stanica/ml.
The method of Claim 1 or 3 wherein the cell culture supernatant is maintained at a pH that is set at X±0.5 wherein X has a value of from 7.15 to 7.20, with the proviso that the pH is set at greater than 7.10. 
Postupak u skladu s patentnim zahtjevom 1 ili 3, pri čemu se supernatant kulture stanica održava na pH X±0.05 pri čemu X ima vrijednost od 7.15 do 7.20, s pretpostavkom da je pH podešen na vrijednost višu od 7.10.
A method for the continuous remote monitoring of the position and advance speed of a pig device (10) inside a pipeline (12) suitable for transporting a pressurized fluid, wherein the pipeline (12) consists of a plurality of pipe sections joined to each other by welding, the method comprising the following steps: 
Postupak kontinuiranog daljinskog praćenja položaja i brzine napredovanja prasice (10) unutar cjevovoda (12) pogodnog za transport fluida pod tlakom, gdje se cjevovod (12) sastoji od više cijevnih odjeljaka, spojenih zajedno zavarivanjem, gdje postupak uključuje sljedeće korake: